The South Korean biopharma industry has come a long way in the past couple of decades. Global out-licensing deals surged more than 21% from just 2020 to 2021 and the country has witnessed the development of its 34th original new drug, contrasting from a time when it was not able to develop any innovative products.
Meanwhile, the number of bioventures has risen to 3,000, while companies such as Samsung BioLogics and Celltrion, Inc....







